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iThe Obama Administration’s 2010 Call Letter for Medicare 
Advantage and Prescription Drug Plans: 
Implications for Beneficiaries
Executive Summary 
Each year, the Centers for Medicare and Medicaid Services (CMS) issues a “Call 
Letter” that functions as a request for proposals to private health insurers and 
organizations that want to sponsor Medicare Advantage (MA) Plans or Medicare 
Prescription Drug Plans (PDPs).  The Call Letter provides potential plan 
sponsors with information to assist them in submitting their bids for the following 
year.  It also discusses CMS policy for implementing related legislative and 
regulatory changes, including relevant provisions in the Medicare Improvements 
for Patients and Providers Act (MIPPA).  CMS uses the Call Letter to highlight 
problem areas from the previous year, express expectations for the coming year, 
and describe its priorities for the coming year.
This policy brief examines key provisions and changes in plan requirements, as 
described by the new Administration in its first Call Letter issued on March 30, 
2009.
As in previous years, the Call Letter discusses rules that plan sponsors need to 
know in order to operate in the Medicare program. The 2010 Call Letter indicates 
an intention to focus on new issues of importance to consumers with an eye 
toward greater enforcement of existing and new rules.
These changes announced by CMS focus on accountability, informed choice 
among beneficiaries and other beneficiary protections, and include the following:
Accountability
• Sponsors that file incomplete and inaccurate plan applications, bids, and 
formularies could be subject to a range of corrective actions.  
• Plans that fail to meet standards for timely resolution of complaints 
recorded through the Health Plan Management System Complaints 
Tracking Module will be considered to be out of compliance with 
regulatory and contractual requirements.
• Plans will be subject to targeted, data-driven and risk-based audits 
focused on enrollment processes, appeals and utilization management 
criteria in formularies.
• Sponsors will be subject to stricter rules for marketing their plans.
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Promoting Informed Health Plan Choices For Beneficiaries.
• Medicare Advantage (MA) sponsors are encouraged to eliminate plans 
with low enrollment or duplicative benefit structures, and limit their 
offerings to no more than three MA plans by plan type in a region, in an 
effort to ease beneficiary confusion.
• Plans are required to use standardized descriptions of the extent of drug 
coverage in the coverage gap or doughnut hole to facilitate comparisons 
across plans.
• Plans are required to publish drug formulary utilization management 
requirements and use standard plan types in plan names to inform 
beneficiaries and promote transparency
Increasing Beneficiary Protections 
• Plans with high cost-sharing requirements for services associated with 
chronic and acute conditions will be reviewed by CMS and will not 
automatically be accepted for 2010, including cost-sharing, even if they 
were approved for 2009. 
• Plans with out-of-pocket expenses capped at more than $3,400, or with 
cost-sharing for certain services higher than Medicare cost-sharing, 
would be subject to greater scrutiny for discriminatory practices. 
• Chronic condition special needs plans will have stricter enrollment 
eligibility criteria and be subject to new standards for their benefit 
packages.
• Private fee-for-service plans will be required to make their cost-sharing 
requirements more transparent, particularly in situations when 
beneficiaries fail to notify a plan prior to receiving treatment; failure by 
plans to comply could result in sanctions or civil monetary penalties. 
• Medication Therapy Management programs will have more detailed 
requirements that address enrollment, targeting, intervention and 
outcomes-reporting and are based on what CMS identified as best 
practices in these areas. 
• Plans will no longer be permitted to use reference-based pricing in their 
formularies, whereby plans add a surcharge to cost-sharing of certain 
prescription drugs. 
The 2010 Call Letter emphasizes compliance with rules, regulations, and 
guidance. CMS states that some problem areas, such as reporting of medical-
loss ratios and reassignment of low-income subsidy individuals, warrant 
additional consideration, and seeks input on how to make the program work 
more efficiently for beneficiaries, plan sponsors, and health care providers. CMS 
indicates it will continue its oversight of marketing and other areas such as 
enrollment and appeals to ensure that beneficiaries receive necessary health 
services.
1The Obama Administration’s 2010 Call Letter for Medicare 
Advantage and Prescription Drug Plans: 
Implications for Beneficiaries
Introduction
Organizations that want to sponsor Medicare Advantage (MA) plans under 
Medicare Part C and/or Prescription Drug Plans (PDP) under Medicare Part D 
must enter into a new contract with the Centers for Medicare & Medicaid 
Services (CMS) each year.1  The contracting process is complex.  Plans must 
submit their applications, which include their pricing bids and their plan benefit 
packages (PBPs), within strict time frames.  CMS must review the information, 
send comments to the sponsors, approve the applications, establish premium 
amounts, and review marketing materials within an equally tight time frame. The 
goal is to have the entire process completed by the end of September so that 
Medicare beneficiaries have the information they need to make health care 
choices at the start of the Parts C and D annual enrollment period on November 
15 of the same year.2  New contract years, referred to as plan years, begin on 
January 1.
The contracting process commences early in the new plan year with the issuance 
by CMS of the Call Letter.  The Call Letter functions as a request for proposals to 
act as Medicare Advantage plans and PDPs for the following year. Hence, the 
Call Letter issued in 2009 is called the 2010 Call Letter.  It provides current and 
potential plan sponsors with information to assist them in submitting their bids.  
The Call Letter discusses legislative and regulatory changes that have recently 
gone into effect or will go into effect for the next plan year as well as CMS 
policies to help implement statutory and regulatory requirements.  CMS uses the 
Call Letter to highlight problem areas from the previous year, to express its 
expectation of plan sponsors for the upcoming year, and, in effect, to describe its 
priorities for monitoring plan compliance with statutory, regulatory, and 
contractual obligations. 
CMS initially releases the Call Letter in draft form, providing interested parties the 
opportunity to comment on the Call Letter, its requirements for plans, and the 
agenda CMS sets out for itself in terms of oversight and enforcement.  Parties 
are given a limited time frame in which to submit comments.  The initial Call 
Letter, released January 8, 2009, was rescinded by the new administration on 
January 22 and reissued on February 23, with comments due to CMS on March 
6.  The final 2010 Call Letter was issued on March 30, 2010.3  CMS indicates 
that it received approximately 190 comments on the draft document from a wide 
range of interested parties, including health plans, consumer groups, states, 
pharmacists, health care providers, and members of Congress. 
2The 2010 Call Letter follows the format of previous Call Letters.
• Section A of the call letter focuses on issues related to Medicare 
Advantage, including the bidding process, audits, the number of plans 
per sponsor, and benefit design.
• Section B of the call letter focuses on Medicare Prescription Drug Plans, 
including the bidding process and formularies. 
• Section C examines issues related to plan marketing and beneficiary 
communications.
The Call Letter discusses new rules that became effective in 2009 or that will 
become effective in 2010 as a result of passage of the Medicare Improvements 
for Patients and Providers Act (MIPPA) of 20094 and of CMS directives.  It 
includes comments on good and poor plan practices and highlights areas for 
oversight and enforcement.
The focus of the Call Letter is on the new guidance plan sponsors will need to 
prepare their contract submissions.  Three areas in which CMS will continue to 
evaluate its policies based on response to its request for comments in the draft 
Call Letter are the following:  methodologies for calculation and dissemination of 
information about plans’ medical loss ratios5; improvements to the reassignment 
process of low-income subsidy eligible individuals whose Part D plan no longer 
qualities for the low-income subsidy; and appropriate methods, for plans that are 
losing members due to  reassignment, for discussing with members how they 
may remain in their current plan and their premium obligations if they choose to 
do so. This brief examines the 2010 Call Letter. Rather than a section-by-section
analysis, the brief examines themes and trends to determine what some of the 
policy changes may indicate for beneficiaries. 
SECTION A – MA, MA-PD, AND COST PLANS
Section A of the draft Call Letter contains provisions relevant to Medicare 
Advantage plans (MA) and other managed care plans.  CMS solicited comments 
on a number of issues relevant to MA plans in the draft version, particularly in 
regard to improving the Part C program for Medicare beneficiaries.  The Call 
Letter also discusses MIPPA changes that go into effect in 2010. 
INCREASED ACCOUNTABILITY
Plan Bidding Process and Audits
Plan Bids and Plan Corrections: Both the 2009 and 2010 Call Letters state that 
plan bids must be submitted by the deadline stated in the Call Letter, and that 
late bids will not be accepted.  Both also indicated that plan sponsors will not be 
able to request plan corrections for the following year after the October 1 
3deadline.  The goal is to have plan benefit packages in sufficient time for CMS to 
include correct and accurate plan information on its web site for the start of the 
annual enrollment period in November.  
If a plan correction is requested, CMS will consider the bid to be incomplete or 
inaccurate, will question the validity of the certification and verification, and will 
question the ability of the sponsor to submit correct bids.  Most important, CMS 
advises sponsors for the first time6 that request of a plan correction will result in 
issuance of a corrective action warning letter.  Corrective action files are posted 
on the CMS website.7
Audit Approach:  The Call Letter states that in 2010 CMS will conduct targeted, 
data-driven and risk-based audits of plans, rather than the routine audits the 
agency previous had conducted.  The focus will include areas such as enrollment 
processes and appeals, which have the greatest potential harm for plan 
enrollees. CMS will target poor performing organizations, and will assess the 
effectiveness of internal monitoring, auditing and other plan compliance 
programs.
CMS states that, in 2010, MA and PDP plan sponsors, as well as cost plans, 
should audit the Part C and Part D data they report to CMS for plan monitoring 
and performance measurement. CMS notes that it has not be able to respond to 
Congressional and other inquiries about costs, availability of services, use of 
services, safety and grievance rates either because of an absence of data or 
because the data submitted by Part D plan sponsors have been of questionable 
validity. To address the issue, CMS will develop data validation specifications to 
ensure reliability, completeness and comparability.  The specifications will be 
phased in, starting with areas of most concern to beneficiaries.8
Sponsors must report the results of their audits, including measures for which 
they do not pass.  CMS indicates that “not pass” on an audit measure will be 
treated as a failure to submit the data.  They may be considered as non-
compliance, and plans may be requested to develop corrective action plans. 
Again, CMS makes information about corrective action plans available on its web 
site.
Although CMS imposes strict standards for audits, the Call Letter does not 
discuss the statutory requirement that at least one-third of MA plans be audited 
annually.9  The Call Letter does not adopt recommendations made by the 
Government Accountability Office (GAO) that would allow CMS to meet the one-
third audit requirement and that would make other improvements such as 
including terms in its contracts for pursuing financial recoveries against plan 
sponsors that have been overpaid. 10
4Quality and Performance Measures 
MIPPA Requirements: MIPPA extended to private fee-for-service (PFFS) and 
Medical Savings Accounts (MSAs) the quality improvement measures applicable 
to other MA plans.  The Call Letter describes the new rules and their applicability 
to PFFS and MSA plans.  The Call Letter is silent, however, concerning the 
reporting of information for could have required all Part C plans to report on and 
disclose information on disparities in the use of health services by plan enrollees, 
and on plan policy, practices and procedures to assist beneficiaries with limited 
English proficiency. 
Response to Complaint Tracking Module:   The Call Letter establishes for 2010 
standards for resolution by Part C and Part D plans of complaints recorded 
through the Health Plan Management System Complaints Tracking Module. 
Plans must comply with strict time frames in at least ninety-five percent (95%) of 
the cases.  Time frames vary with the designation of the complaint - immediate 
need, urgent need, unclassified – with CMS reserving the right to reclassify any 
complaint that does not fit the definitions of immediate need and urgent need 
specified in the Call Letter. CMS will consider plans that fail to meet the threshold 
as out of compliance with a number of requirements, including those related to 
enrollment, coverage and organization determinations, appeals, and claims 
processing.  This provision is significant for beneficiaries.  It establishes set time 
frames by which problems must be resolved, helping to ensure that beneficiaries 
have access to medically necessary services. It also points out the high regard 
CMS places on timely complaint resolution, since plans that do not meet the 
thresholds will be considered out of compliance. 
Grievance, Organization and Coverage Determinations, and Appeals:  Previous 
Call Letters have addressed a number of beneficiary concerns about Part C and 
Part D plan failure to implement and comply with regulations concerning 
grievances, determinations and appeals.  The 2010 Call Letter spends little time 
on these issues. The draft Call Letter required all plans to send the relevant 
Evidence of Coverage and formulary on a CD with every file appealed to the 
independent review entity (IRE). The idea was to expedite decisions at both the 
IRE and administrative law judge (ALJ) levels of review by ensuring that 
complete and accurate information is available to the reviewers. CMS eased the 
requirement in the final version, however, and simply extended through 2010 the 
previous recommendation that plans send the complete COS and formulary, if 
applicable.
CMS could have included in the Call Letter a reminder that plans must comply 
with the regulatory time frames, and that the time frames represent hours and 
calendar days, not business hours and business days.  Although CMS indicates 
in the section on responses to the complaint tracking module that plans that fail 
to comply may be found out of compliance with appeals provisions, CMS could 
also have included that reminder in this section.  As it did  in other sections of the 
5Call Letter, CMS could have requested information about the need to issue 
proposed regulations to make the process work more efficiently for beneficiaries, 
particularly with regard to the notice of appeal rights. 
PROMOTING INFORMED CHOICE AND EASE IN ENROLLMENT
Both Part C and Part D are premised on beneficiaries having a choice of options 
in order to enroll in the plan that best meets their needs. Yet beneficiaries have 
difficulty differentiating among the multiple plan offerings by the same sponsor, 
generally because the differences in benefit packages are subtle, and the plans 
have the same or very similar names.  Additionally, when people are presented 
with too many choices they may end up making an inappropriate choice or no 
choice at all. A number of new recommendations in the 2010 Call Letter are 
designed to improve the choice and enrollment processes. 
Multiple and Low Enrollment Plan Offerings:  CMS recommends in the Call Letter 
that plan sponsors limit plan offerings in several ways.  First, CMS states that 
plan sponsors should eliminate for 2010 plan offerings that have low enrollments.  
CMS notes that these plans may not have the financial stability to provide the 
quality health care to which beneficiaries are entitled.  According to CMS, there 
are “currently large numbers of plan offerings with fewer than 10 enrollees.”11
CMS regulations require a minimum of 5,000 beneficiaries enrolled in each 
organization after three years, and 1,500 enrollees in rural areas.12  CMS could 
go further than just strongly encouraging plan sponsors not to submit bids for 
such plans in 2010. CMS has the statutory authority to deny renewal of contracts 
for plans that do not meet the statutory standards, and CMS could exercise its 
authority not to renew. 
Second, CMS also states that sponsors should eliminate plans that are 
duplicative of other plans they offer, and should ensure that the differences in 
plan offerings are transparent to plan enrollees. The Call Letter cites as 
examples plans with or without drug benefits or specific supplemental benefit 
options as well as different plan benefit types. Again, CMS can take action in this 
regard, by not renewing or approving multiple plan offerings from the same 
sponsor where the benefit structures do not vary significantly, and by developing 
standardized marketing materials that make differences in costs and benefits 
clear.
In the draft Call Letter, CMS solicited comments on whether it should issue rules 
that would limit plan sponsors to no more than a specified number of benefit 
designs in a given service area.  The final Call Letter includes the “expectation” 
that plan sponsors offer no more than three MA plans of each plan type in each 
market, and that the plans offered can be easily distinguished based on plan 
type, benefit package, and access. Additionally, CMS says that, based on the 
6comments received, the agency is considering issuing proposed rules concerning 
the number of benefit designs and consolidation of low enrollment plans.
Providing Information About Plan Changes:  Plans send their current enrollees 
two important information tools that describe in detail the benefits they cover.  
The Annual Notice of Change (ANOC), sent in the fall before the annual 
enrollment period begins, explains plan changes in benefit structure, premiums, 
cost-sharing and formulary for the upcoming plan year.  The ANOC is designed 
to be used by enrollees to help decide whether to remain in their current plan.  It 
is often a dense document, and may be too dense for some beneficiaries to use 
effectively. The second informational tool, the Evidence of Coverage (EOC), is 
the formal, detailed plan document that serves as the explanation of plan benefits 
and costs, plan procedures, and beneficiary rights and protections.  It, too, is a 
lengthy document with complex information. 
When CMS first announced the use of a combined ANOC/EOC, beneficiary 
organizations filed objections in their comments to previous Call Letters that the 
combined document would be too long and that information about plan changes 
would get lost.  Beneficiary advocates believe that CMS could have helped to 
highlight benefit cost-sharing and structural changes, and therefore eased some 
of the complexities of choosing a health plan, by requiring that the ANOC and 
EOC be sent separately.  Despite continued objections by beneficiary 
organizations, CMS is requiring plans to submit and use the combined 
ANOC/EOC again for 2010.
Mandatory Use of the Online Enrollment Center:  The 2010 Call Letter requires 
for the first time that almost all Part C and Part D plans accept enrollments made 
through the Medicare Plan Finder that is available on the CMS website for 
Medicare beneficiaries. Plan sponsors are required to download pending 
enrollments at least once a day.  Some beneficiaries have reported in the past 
that when the beneficiary calls the plan to enroll, some plans enroll them in 
different plans than what the beneficiary selected.  The new policy is designed to 
protect against such situations and to help the enrollment process move 
smoothly.
The draft Call Letter required all plans to accept on-line enrollment through the 
CMS website.  The final Call Letter made such use optional for plans that require 
additional eligibility information, such as special needs plans and religious 
fraternal benefit plans.  The final Call Letter also indicates that MA plans that are 
available only to employer groups cannot use on-line enrollment to prevent 
confusion for other beneficiaries who are not eligible to enroll in such plans.  
Medicare Cost plans and Medical Savings Account plans also cannot participate 
in on-line enrollment because they use a different enrollment format and require 
additional information.13
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eliminate a low-enrollment or duplicative plan bid, or if CMS terminates a contract 
with a plan, enrollees in the terminated plan must make a choice about how to 
receive their health care.  The issue also arises in the context of Part D if a PDP 
sponsor decides not to renew a plan’s contract for the following year or if the 
contract is terminated by CMS.
CMS initially used “passive enrollment,” that is, enrollment by CMS, in 2005 to 
place beneficiaries, who did not voluntarily elect an MA plan, into a Medicare 
special needs plan; this resulted in litigation.14  Medicare beneficiary advocates 
commented on the draft 2010 Call Letter, on previous Call Letters, and on 
proposed regulations that CMS lacks the authority to place individuals in an MA 
plan that they did not choose for themselves. The Medicare statute makes 
enrollment in an MA plan voluntary; an individual who does not make an election 
is deemed to elect to remain in traditional Medicare.  The statute also says that 
once someone elects an MA plan, that election will continue until the individual 
changes the election or the plan no longer serves the area in which the individual 
resides.  CMS guidance creates a special enrollment period (SEP) for enrollees 
whose health plan is terminated or is non-renewing.  The guidance states that 
plan enrollees who do not elect a new plan before the end of the plan’s contract 
are to be defaulted into traditional Medicare.15
The Call Letter states that, where appropriate, CMS will authorize the transition 
of exiting plan enrollees to another plan offered by the same sponsor.  The Letter 
acknowledges that affected beneficiaries have a SEP to change plans under the 
existing CMS policy on plan non-renewals.  The Call Letter also states that where 
a plan sponsor does not offer another, similar plan, enrollees will be returned to 
traditional Medicare unless they elect a different plan. 
BENEFICIARY PROTECTIONS 
Several provisions in the Call Letter implement and expand upon new and 
existing protections for beneficiaries with regard to cost-sharing, benefit design, 
and transparency of information. 
Cost-sharing for Dual Eligibles:  Section 165 of  MIPPA prohibits special needs 
plans (SNPs) for dual eligible individuals from imposing cost-sharing 
requirements on dual eligibles or Qualified Medicare Beneficiaries that would 
exceed the amounts permitted under the State Medicaid plan if the individual 
were not enrolled in the Dual-SNP. The MIPPA provision is effective January 1, 
2010.  Provisions of both Medicare and Medicaid that existed before MIPPA as 
well as extensive CMS guidance are much broader.  They include cost-sharing 
limitations for all dual eligibles, whether in traditional Medicare or any kind of 
Medicare Advantage plan (regardless of whether it is a SNP). The amount and 
nature of the cost-sharing protections vary based on a variety of complicated 
factors, and were set forth in CMS Guidance issued in May 2008.16
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citing two interim final regulations issued by CMS in September 2008,17 applies 
the limitation on cost-sharing to all MA plans, not merely to Special Needs Plans 
for dual-eligibles, as included in MIPPA. The Call Letter aims to reduce billing 
problems encountered by dual eligibles by requiring a provider contract provision 
that enrollees not be held liable for cost-sharing that should be paid by Medicaid 
programs. Plans must inform providers of Medicare and Medicaid benefits and 
eligibility rules on a frequent basis since many are not aware of how the rules 
work.
Some other provisions could strengthen this section. The Call Letter could refer 
to the regulatory language that all contracts must state that the providers will "(A) 
Accept the MA plan payment as payment in full, or (B) Bill the appropriate State 
source."18 It could also require all plans serving dual eligibles to work with the 
Medicaid agency in the state in which they operate to assure that their statement 
of Medicaid benefits provided to providers is accurate. 
Limit on Out-of-pocket Costs:  The section on cost-sharing guidance continues 
efforts by CMS to improve transparency so that beneficiaries may predict more 
easily their out-of-pocket (OOP) costs if they were to enroll in a particular plan. 
There are two separate issues in determining OOP costs.  As the GAO found, 
some MA plans charge cost-sharing that is greater than what beneficiaries would 
pay under the traditional Medicare program.  And, while some plans have caps 
on OOP costs, they may also exclude some services from the caps, so that 
beneficiary costs continue to accrue even after the cap is reached.19
The 2009 Call Letter stated that plan sponsors may not design benefit packages 
to discourage enrollment by people with severe or chronic conditions, and that 
cost sharing or deductibles determined to be discriminatory would not be 
approved.  The 2010 Call Letter indicates that it will continue to review cost 
sharing for services associated with chronic and acute conditions, and those that 
are high utilization and high cost.  Additionally, benefit designs, including cost-
sharing, approved for 2009 will not automatically be accepted for 2010.  In 
addition, the Call Letter says that it will “likely” not consider a co-insurance 
amount to be discriminatory if the plan has an overall OOP maximum of $3,400, 
the co-insurance for certain services (renal dialysis, Part B drugs, psychiatric 
hospitalization, and skilled nursing facility services) does not exceed the co-
insurance under traditional Medicare, and the plan does not carve out any 
services covered under Part A and Part B from its OOP maximum.  $3,400 
represents the 85th percentile of projected beneficiary spending in 2010. 
As with several other issues, CMS indicates that it is considering amending 
regulations that would impose a requirement for an out-of-pocket amount.  The 
regulations could reduce the OOP maximum from its current level. The $3,400 
OOP maximum represents approximately 16 percent of income for the 46 
percent of Medicare beneficiaries with incomes below 200 percent of the federal 
9poverty level ($21,660/individual in 2009).20 Proposed regulations could 
strengthen out-of-pocket protections by stating clearly the services for which 
plans may not charge more than traditional Medicare.  For example, the 
regulation could include the services CMS said it would review as services 
associated with chronic and acute conditions. 
Benefit Design: The Call Letter addresses several issues involving the design of 
a MA plan’s benefit package.  These include incentives to encourage the use of 
preventive benefits, supplemental over-the-counter benefit packages, 
supplemental home infusion drug packages, and the use of rebate dollars to 
enhance the traditional Part A and Part B benefit package. 
In keeping with efforts by CMS over the past several years to promote the use of 
Medicare preventive benefits, the Call Letter contains directions about the use of 
incentives by MA plan sponsors to encourage plan enrollees to use Medicare-
covered preventive benefits. CMS reminds plans that the emphasis of their 
benefit package should be the provision of Part A and B covered benefits at a 
lower cost. The use of incentives should be directed at enrollees, not potential 
enrollees, and should be directed towards using the services and not an 
outcome.  Incentives are not to be advertised as a plan benefit or included in the 
bid as a benefit, but costs related to incentives are to be included with other non-
covered benefit costs.
CMS also updates the guidance provided in the 2009 Call Letter on supplemental 
over-the-counter (OTC) benefit packages. The updated guidance helps clarify 
when a plan may provide a supplemental OTC benefit and how the benefit 
should be provided.  CMS indicates that it will no longer use lists of categories of 
OTC items from other sources, and includes a listing of categories in Appendix I 
to the draft Call Letter. This change aims to standardize the items that may be 
offered and may help in the beneficiary comparison process.  The Call Letter also 
precludes the offering of a debit card for OTC benefits that is usable in only one 
pharmacy chain; the stated intent of this prohibition is to preclude the steering of 
beneficiaries to that pharmacy chain. 
The Call Letter also addresses the confusion surrounding payment for home 
infusion drugs. In traditional Medicare, if the drugs are covered under the Part B 
durable medical equipment (DME) benefit, then Medicare pays for both the home 
infusion drugs and the durable medical equipment through which they are 
delivered.  If the home infusion drugs are covered under Part D, however, the 
Part D plan pays only for the drugs, and the beneficiary is responsible for 
obtaining and paying for the delivery mechanism. Despite the fact that MA-PDs 
are supposed to provide all Parts A, B and D-covered services, some plans reject 
payment for home infusion drugs as not covered under Part D when the drugs 
may be coverable under Part B, or they will cover the drug under Part D but not 
the related supplies.21 The Call Letter requires plans with a Part C mandatory 
supplemental benefit that bundles home infusion drugs to pay for the home 
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infusion drugs under Part C, rather than under Part D as would happen if the 
drugs and supplies were not bundled.  The bundled package must include the 
drugs and the supplies needed to provide the drugs.  CMS waives the definition 
of a Part D drug with regard to home infusion drugs covered under a bundled 
package, provided that the plan applies no cost-sharing for the bundled services.  
Plans must ensure that even enrollees who are long-term care facility residents 
are eligible for the bundled services.  CMS stated that policy is being adopted to 
make it easier for beneficiaries to calculate whether they would be better off with 
the supplemental Part C benefit or having the drugs covered under Part D.  This 
policy could help beneficiaries in nursing facilities since that Medicare Part B 
does not cover DME, and the drugs supplied through DME, for such 
beneficiaries. 22
Another benefit design issue concerns the reallocation of rebate dollars towards 
benefits after CMS determines the MA plan bid amount. The Call Letter reminds 
plans that they cannot use the rebate re-allocation process to change their basic 
Medicare benefit package and premium.  CMS reiterates its admonition from 
previous years against reallocating rebate reductions by increasing cost sharing 
for more limited-use services such as inpatient, skilled nursing facility (SNF), and 
home health care unless reductions in non-Medicare covered benefits or 
increases in cost-sharing for widely used services have been made first.  As in 
the past, CMS says that the first priority of rebate reductions should be to reduce 
the Part D premium to the lower amount targeted by the plan sponsor. While 
reduction of Part D premiums may appear to be a beneficiary-friendly priority, the 
policy is not without problems. Plans that have to increase their cost sharing for 
more costly services in order to keep a $0 or reduced Part D premium may be 
discriminating against sicker beneficiaries who utilize these services.   
CHANGES MADE BY MIPPA 
CMS devotes a portion of the Call Letter to explain the new plan requirements 
contained in the MIPPA, in interim final rules issued by CMS on September 18, 
2008 and in final rules published January 12, 2009.23  Some of the MIPPA 
provisions concerning reporting of quality measures were discussed in an earlier 
section of the paper.  This portion of the paper focuses on implementation of 
MIPPA and regulatory changes for Special Needs Plans (SNPs) and Private Fee-
for-Service (PFFS) plans.  It includes suggestions on how CMS could strengthen 
the MIPPA protections in future years. 
Special Needs Plans: It is interesting to note that the section of the Call Letter 
discussing SNPs includes many references to new plans for the 2010 plan year.  
MIPPA section 164(b), however, precludes the designation of new plans in the 
2010 plan year, continuing the moratorium first put in place in the Medicare, 
Medicaid and SCHIP Extension Act of 2007 governing the time period January 1, 
2008 - December 31, 2009.  It is unclear why CMS ignores the moratorium.  
CMS could have eliminated all references in the SNP section to new plans.
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Models of Care: One of the new requirements for SNPs is that they have an 
evidence-based model of care (MOC) that is appropriate to each SNP. The Call 
Letter indicates that the requirement applies to new and existing SNPs.
CMS in future years could strengthen the Call Letter language about MOC 
requirements in a number of ways. First, the language concerning the 
development of the care plan could be stronger than requiring consultation with 
the individual “as feasible.”  The plans could be required to consult with the 
individual unless such consultation is impossible and with anyone the individual 
chooses to have involved in the care planning, including a delegated surrogate. 
Second, assessment and annual reassessment is required by MIPPA; CMS 
could add language that requires reassessment as needed when the 
beneficiary's circumstances change. Given that SNPs serve the most vulnerable 
populations, more than an annual reassessment may be needed to ensure that 
the plan is providing all necessary services. Third, plans could be required to 
demonstrate how they will serve people with limited English proficiency who are 
disproportionately represented in the dual eligible population.  Fourth, since 
models of care are what distinguish SNPs from other MA plans or delivery 
models, CMS could require plans to describe their MOCs in all plan marketing 
materials and make them publicly available.  CMS could have included more 
detail in the Call Letter concerning the review and subsequent audit of MOCs to 
ensure that SNPs are providing the special services for which they were 
intended.
Institutional SNP – Level of Care Assessment Tool:  MIPPA requires all 
institutional SNPs (I-SNPs) to conduct an assessment to determine the eligibility 
for beneficiaries who live in the community but need a skilled level of care.  The 
statute also requires the I-SNP sponsor to use the state assessment tool for the 
state in which the plan operates.  The Call Letter states that CMS will monitor to 
make sure the plans use the appropriate assessment, with plan sponsors bearing 
the burden of demonstrating that they follow the practice of the state. 
Furthermore, I-SNPs cannot provide bonuses or payment differentials to 
independent assessment entities for qualifying members for the I-SNP, and must 
use credentialed agents for conducting the assessment.
SNP Quality Improvement and Chronic Care Improvement Programs:  The Call 
Letter discusses the MIPPA and CMS regulatory requirements concerning quality 
improvement programs (QIP) and care management, and indicates that it may 
focus increased oversight and audit activities on monitoring of these programs.
The Call Letter provides examples of QIPs for the three kinds of SNPs.  The 
examples provided in the Call Letter would not necessarily assess the 
uniqueness of the SNP to address the needs of the appropriate population. The 
first example of a QIP for dual eligible SNPs suggests an evaluation of the effect 
of add-on-transportation services on utilization rates of primary care and 
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preventive health services.  Since many state Medicaid programs already pay for 
transportation services, in those states, the add-on transportation services from 
the SNP may not provide any additional benefit than already exists, for full dual 
eligibles.   
The examples of QIPs for institutional SNPs also may not accurately assess 
whether the I-SNP is providing something of extra value to its enrollees. One 
example suggests evaluating the effect of an annual health risk assessment.  
However, provisions in the Nursing Home Reform Law concerning the frequency 
and timing of assessments by the SNFs suggest that an annual health risk 
assessment by the SNP for non-institutional beneficiaries may not be sufficient to 
identify problems before adverse outcomes occur.  The second example 
provided in the Call Letter, whether the SNP “sent timely reports on beneficiary 
health status to the interdisciplinary care team resulting in a continuous update of 
the individualized care plan,” duplicates the requirement imposed on SNFs by the 
Nursing Home Reform Act to assess residents and update their care plans, 
annually, quarterly, and on significant change in a resident’s condition.24
Chronic Condition SNPs (C-SNPs):  The Call Letter advises C-SNPS that they 
must demonstrate their special attributes in order to be of value to their enrollees 
and to get the special marketing and enrollment accommodations that are 
accorded to them. The Call Letter further advises that their benefit packages 
must include more than just Part A and Part B services, and must be more 
extensive than the care coordination required of all MA coordinated care plans.
The C-SNPS that are offered in 2010 will have to be structured around 15 severe 
or disabling conditions that were identified by CMS as meeting the statutory 
definition of severe or disabling chronic condition.  Pursuant to a requirement in 
MIPPA, CMS convened a panel to identify the conditions.  Advocacy 
organizations have concerns that, without additional clarifications, C-SNPs can 
design plans around the 15 severe or disabling chronic conditions that are not 
distinguishable from other MA plans. CMS places additional limitations on the 
populations that C-SNPs may enroll to discourage C-SNPs that are “a general 
market product rather than a product tailored for a particular population.”
Acknowledging the continuing concern regarding C-SNP enrollment of 
beneficiaries who do not have the chronic condition to be served by the C-SNP, 
CMS states that it will conduct focused audits to determine that plans are 
verifying that enrollees have the conditions the C-SNP has been approved to 
serve.
Requirement for Dual-Eligible SNPs (D-SNPs) to Contract with State Medicaid 
Agencies:  MIPPA adds new requirements for 2010 that define the relationship 
between D-SNPs and state Medicaid agencies.  CMS states in the Call Letter 
that D–SNPs best serve their population when they have strong connections to 
the Medicaid program in the state in which they operate.  MIPPA requires that 
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plans tell prospective enrollees the benefits and cost sharing protections under 
their Medicaid program and which of those are offered under the SNP.  However, 
as CMS has noted elsewhere, SNPs must provide the same cost-sharing 
protections as are available to duals under Medicaid and under CMS regulations.  
The Call Letter language as to the nature of the state-SNP 
collaboration/cooperation could be stronger.  Plans are required by regulation to 
have eligibility verification arrangements with states and to identify and share 
information about Medicaid provider participation.  The latter requirement should 
prevent plans from being approved as D-SNPs if they have no Medicaid 
providers in their networks.  The statutory requirement for a contract with the 
state is waived for plans that do not expand their service area.  CMS could still 
require all plans to coordinate with the state in the above mentioned areas, even 
if it is through a less formal arrangement than a contract.  Any MA plan serving 
dual eligibles, but most especially D-SNPs, should have the capacity to help 
duals navigate both Medicare and Medicaid benefits successfully to get the 
services they need. 
CMS also indicates in the Call Letter that it will create a resource contact, 
through the contracting process, to work with states to develop model and best 
practices for state-SNP relationships.  This action is to implement a MIPPA 
requirement to provide resources to states.
Enrollment requirements for 2010: The Call Letter sets forth general guidance for 
transitioning of SNP enrollees from 2009 to 2010 and indicates that more 
detailed guidance will be issued later in the year.  The general guidance is 
designed to ensure that SNP enrollees in 2010 are members of the group that 
the SNP is authorized to serve; that the transition for individuals who no longer 
meet the eligibility criteria is seamless; and that affected plan enrollees receive 
clear and timely information about their options.  While CMS discusses the 
general guidance in terms of individuals who no longer meet the conditions 
targeted by a C-SNP, the guidance can also apply to individuals who no longer 
are eligible for a D-SNP or an I-SNP. 
Under the general rules, individuals who continue to meet the eligibility criteria, 
either because the SNP remains the same or because the targeted condition is 
subsumed into a broader SNP, would remain in the SNP unless they elect 
another option.  If a C-SNP that targeted multiple conditions breaks up into 
separate plans, 2009 plan enrollees would be passively enrolled to the new plan 
that targets their condition, unless they elect a different option.  Enrollees in the 
2009 plan who do not meet the new categories would be ineligible to enroll in any 
of the 2010 SNPs. 
Beneficiary organizations in their comments on the draft 2010 Call Letter raised 
concerns about the automatic assignment into different MA plans of 2009 plan 
enrollees who no longer meet the eligibility criteria of the new SNP, or whose 
plan sponsor terminated all SNP offerings.  CMS indicated that it will consider 
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proposals for passive enrollment into a different plan in 2010 if the sponsoring 
organization can establish to the satisfaction of CMS that the plan into which they 
will be enrolled has similar benefits, formularies, premiums, and network rules.  
CMS also states that affected beneficiaries have a special election period (SEP) 
whenever they transition to a different SNP or MA plan, or return to traditional 
Medicare.
CMS, in its future guidance, can address concerns about the existing SEP for C-
SNPs, which allows enrollment at any time into a C-SNP, but which does not 
provide for disenrollment at times outside the general enrollment period.  
Individuals who enroll mid-year in a C-SNP that is not appropriate for them must 
remain in that plan until the annual enrollment period.  If the SEP is retained, 
CMS could add a SEP for disenrollment at any time.  The current SEP has led to 
year-round marketing of C-SNPs, sometimes inappropriately, and resulted in 
concerns that plans are being marketed to people who may not be eligible to 
enroll in them.25   D-SNPs and I-SNPs may enroll year round because the 
populations they target, duals and individuals in institutions, are entitled to the 
SEP.  Unlike the SEP for C-SNPs, the SEP for D-SNPs and I-SNPs is not 
specific to any particular type of plan and allows the dual or institutionalized 
individual to enroll in or disenroll from all MA plans, except MSAs, at any time. 
The SEP for C-SNPs is problematic because it allows only for enrollment and not 
for disenrollment.  Individuals who enroll mid-year in a C-SNP that is not 
appropriate for them must remain in that plan until the annual enrollment period.
Private Fee-for-Service (PFFS) Plans: MIPPA made a number of significant 
changes to PFFS plans.  Effective January 1, 2011, most PFFS plans must 
establish contracts with providers.  The Call Letter discusses the changes and 
how CMS intends to implement them. The Call Letter discusses two problem 
areas related to PFFS plans:  provider payment and prior notification. 
Provider Payment:  CMS acknowledges receipt of numerous complaints that 
PFFS plans are not paying non-contract providers the traditional Medicare rate 
as required by statute.  The Call Letter reminds plan sponsors that failure to pay 
the appropriate rates is a compliance matter, and that the agency previously 
issued a program memorandum concerning the process for resolving provider 
payment disputes.  The Call Letter reiterates the expectation that plan sponsors 
will cooperate fully with the contractor that serves as the independent review 
entity for reimbursement adjudications. 
Prior Notification:  The Call Letter provides clarification concerning the difference 
between prior authorization/referral and prior notification, and reminds PFFS 
plans that they are prohibited from requiring prior authorization or referral.  Under 
prior notification practices, plans charge increased cost-sharing for certain high-
cost items and services if beneficiaries do not notify the plan in advance of 
obtaining those items and services.  CMS reminds plans that they must cover a 
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service if they did not receive prior notification; the only difference is in the cost-
sharing they may charge.
The prior notification process may be burdensome for some beneficiaries 
experiencing a health care crisis.  Prior notification requirements and cost-
sharing variations may not be transparent to enrollees, and the process for 
providing prior notification may not be explained adequately.  Providers may be 
unaware of prior notification requirements when they prescribe or order an item 
or service for the beneficiary.  CMS says it expects that PFFS will include in their 
marketing materials the cost sharing amount if prior notification procedures are 
not followed.  Plans that do not clearly list prior notification policies or that treat 
the policies as prior authorization requirements will be subject to sanctions or civil 
money penalties. 
CMS indicates that it is considering whether to issue proposed rules to prohibit 
the use of prior notification.  If prior notification is not prohibited, CMS could 
include in future guidance increased transparency requirements, such as clearer 
notices in marketing materials, and caps on the amount plans may charge if prior 
notice is not received.26
SECTION B – 2010 PRESCRIPTION DRUG PLANS
Section B of the Call Letter contains the provisions that are relevant to Part D 
prescription drug plans (PDPs).  With the exception of the sections on plan bids 
and formulary submissions discussed earlier, this section contains few new 
policies for PDP sponsors.  Some of the additional beneficiary protections, such 
as those involving utilization management criteria, are extensions of protections 
included in previous Call Letters.  
INCREASED ACCOUNTABILITY
Plan Bidding Process and Audits: The 2009 Call Letter provided little guidance 
about the bidding process.  CMS reminded plan sponsors of the need to comply 
with the instructions for submitting contracts and of the need to submit accurate, 
timely materials.  Plan sponsors were warned that if they did not include all of the 
required information they might not get included in the Medicare & You
Handbook, which is sent to every Medicare beneficiary in advance of the annual 
enrollment period in the fall. 
The 2009 Call Letter addressed timely formulary submissions separately.  
Sponsors whose formulary submissions were untimely were informed that they 
“may face a CMS determination” that their bids could not be approved, resulting 
in the termination of their contract at the end of the plan year.  CMS “would 
decline” to enter into contracts with new applicants that did not meet formulary 
submission deadlines. 
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The 2010 Call Letter, on the other hand, outlines substantial problems with 
application submissions by Part D sponsors. It indicates that, since 
implementation of Part D began in 2005, some plan sponsors submitted required 
documents that were so incomplete or inaccurate that they failed to constitute a 
valid, timely submission.  CMS states that some sponsors might have knowingly 
submitted incomplete or inaccurate information to meet timelines and avoid non-
renewal of the contract.  For 2010, CMS will consider the completeness and 
accuracy of the application, formulary, and bid in determining whether a deadline 
has been met.  The Call Letter includes examples of invalid submissions.  
Applications that include blank documents or blank spreadsheets will be denied 
as not meeting the definition of a completed application.27
The 2010 Call Letter is more definitive in regard to formulary submissions and 
goes beyond the timeliness of the submission.  CMS will not consider formulary 
submissions that do not show a good faith effort to provide a formulary that 
meets the requirements set out in the Part D Manual. Examples of inadequate 
formularies are those that include only one Part D drug in the majority of the 
formulary categories and classes or that include significantly fewer drugs than 
other Part D formularies.  If a formulary submission is inadequate, CMS will 
either not renew the sponsor’s existing contract or not enter into a new contract 
for failure to submit a timely formulary.  CMS further advises that such a decision 
is not appealable.28  Additionally, all contracts must be linked to the appropriate 
formulary.  CMS will not check on contracts without formulary links, and those 
without timely links will be denied. 
If, as the 2010 Call Letter indicates, problems have been apparent in the 
submission of bids since the inception of Part D, then CMS did not previously 
enforce the legal requirements for applying to offer a Part D plan.  The 2010 Call 
Letter states clearly that the practices of some plan sponsors will no longer be 
tolerated.
Processing of Payment Requests:  The Call Letter addresses two issues 
involving payment of claims. The first involves payment of pharmacy claims. Plan 
sponsors are reminded of the MIPPA requirement that, effective January 1, 2010, 
they must make prompt payments for retail pharmacy claims.  MIPPA also 
requires that, effective on January 1, 2010, long-term care pharmacies are 
accorded between 30 and 90 days to submit claims for reimbursement. 
The second issue involves processing of out-of-network reimbursement requests 
made by plan enrollees. CMS discusses plan compliance problems related to the 
time frames for reimbursement for out-of-network claims, and extends the time 
frames beyond those required by the regulations. The intent of CMS is to ensure 
that beneficiaries receive their reimbursements without having to go through the 
full appeals process.  However, this contract provision modifies existing rules that 
went through the notice and comment rulemaking process.  Federal law 
generally requires that existing regulations be modified through the issuance of a 
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notice of proposed rulemaking, which gives the public an opportunity to comment 
on the proposed change.
Quality and Performance Measures:  The Call Letter indicates that CMS will be 
implementing new reporting requirements for 2010 based on proposed 
requirements published in the Federal Register for comment in January 2009.  
Additionally, CMS adds new expectations for quality assurance requirements 
involving concurrent drug utilization review, retrospective drug utilization review, 
and medication error identification and reduction. 
The response times for complaints filed under the complaint tracking module, 
discussed under the section on Medicare Advantage plans, are the same for Part 
D plans. 
Prohibition of Mid-Year Enrollment by State Pharmaceutical Assistance 
Programs (SPAPs):  The Call Letter states that, as a result of complaints from 
Part D sponsors about SPAPs performing large numbers of mid-year plan 
enrollment changes, CMS is discouraging SPAPs with authority to make plan 
enrollments from making such mid-year changes.  Additionally, CMS warns 
SPAPs that if they continue to make substantial mid-year changes, CMS may 
determine that the SPAPs fail to meet the definition of an SPAP.  If that happens, 
payments made by these programs will not count towards the catastrophic 
coverage limit for SPAP enrollees. 
SPAPs may change Part D enrollment for their SPAP enrollees during the plan 
year for a number of reasons, including if the plan did not cover the drugs 
needed by the individuals.  However, such action may result in confusion on the 
part of plans.  CMS could have announced it would investigate the reasons for 
such action as part of its increased oversight and accountability efforts. 
PROMOTING INFORMED CHOICE AND EASE IN ENROLLMENT
Beneficiary Understanding of Benefits: The 2010 Call Letter places some focus 
on making sure that Medicare beneficiaries understand the information they need 
to choose and access drug coverage. In a new Call Letter section on beneficiary 
understanding of Part D benefits and the labeling of benefit designs, CMS 
discusses the four benefit types set out in its regulation.  CMS further 
acknowledges that these distinctions do not provide all of the information 
beneficiaries use to choose a plan.  For example, they do not indicate which 
drugs are on the plan’s formulary or which pharmacies are in the plan’s network. 
The Call Letter includes a chart used in 2009 to describe levels of coverage in 
the coverage gap (i.e., “doughnut hole”).  While the chart for 2009 is a good first 
step, the chart itself could be clarified.  CMS says that it will continue to review 
comments regarding the calculation of gap coverage levels. 
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CMS also says that it is interested in receiving comments on the post-enrollment 
provision of benefits information to plan enrollees.  They are particularly 
interested in how the Explanation of Benefits can be used to convey information. 
BENEFICIARY PROTECTIONS
The 2010 Call Letter includes provisions designed to provide additional 
protections for beneficiaries.  A number of those concern formulary issues and 
access to prescribed medications. 
Access to Covered Part D Drugs:  In 2006 CMS designated six classes of drugs 
as six classes of clinical concern.  Drug plan sponsors are required to include all 
or substantially all drugs within those six classes on their formularies.  MIPPA 
codified this requirement but was interpreted by some as possibly including more 
classes in the coverage requirement than just the six previously designated by 
CMS.  The 2010 Call Letter states that for 2010 there will be no change in the six 
classes from those identified in the CMS guidance manual.
CMS proposes, starting in January 2010, to reject claims for national drug codes 
for which the Food and Drug Administration (FDA) is unable to provide regulatory 
status determinations through their regular processes.  CMS states that plan 
sponsors should consider proper FDA listings concerning national drug codes 
when making a coverage determination.  The Call Letter cautions current plan 
sponsors that any changes would apply to 2010, not 2009, and advises them to 
provide notice and information to pharmacy benefit managers and network 
pharmacies concerning national drug codes the sponsors decide not to cover 
under Part D. 
CMS also advises of revisions to the formulary reference file to eliminate 
duplicate codes for the same drugs or to remove inactive or obsolete codes. 
Transitions:  The Call Letter continues efforts to ensure access to prescriptions 
when a beneficiary is faced with formulary changes.  Starting for the 2010 
contract year, plan sponsors will have the option to send required transition fill 
notices to network long-term care (LTC) pharmacies.  This process may allow 
pharmacies to act more quickly to seek an exception or to have the medication 
filled. Notice to the pharmacy will be sent in addition to the model transition 
notice that is mailed to long-term care facility residents within three business 
days after a transition fill has occurred.  Plan sponsors that choose to provide 
notice to the LTC pharmacy as well as to the enrollee will have to document the 
pharmacies’ willingness to receive the notices, maintain electronic 
communications with the pharmacy once the transition fill has occurred, and be 
able to demonstrate that notice has been provided to the beneficiary.
Plan sponsors that change formularies for a subsequent plan year have transition 
requirements with regard to their current enrollees.  The 2010 Call Letter clarifies 
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that the transition requirements also apply to prior authorization and step therapy 
restrictions that are added to drugs on the existing formulary.  CMS could apply 
the transition requirements to new quantity limits as well, or require plans to 
advise the beneficiary of coverage changes in the specific drugs they take. 
Specialty Tier Threshold: When drug plan sponsors utilize a specialty tier for 
high-cost drugs, plan enrollees who rely on these drugs pay high cost-sharing for 
the drugs, ranging from 25% to 33% of the cost of the drug.  In addition, current 
CMS regulations preclude beneficiaries from seeking a tiering exception for these 
drugs as a way to reduce the cost-sharing amount.  The Medicare Payment 
Advisory Commission (MedPAC) issued a recent report that found that four 
classes of drugs (antineoplastics, immunologics, antivirals, and antibacterials) 
account for two-thirds of specialty tier drugs. They also found that specialty tier 
drugs vary greatly from plan to plan, with 40% of such drugs being listed on a 
specialty tier in fewer than half of all plans. Additionally, specialty tier drugs are 
subject to utilization management much more frequently than other drugs.29
The Call Letter states that CMS will continue to analyze and evaluate the 
specialty tier for high cost and unique drugs, and it will maintain the $600 
threshold for drugs to be placed on a specialty tier.  However, as part of its 
formulary review, CMS will evaluate formularies to ensure that they do not 
discourage certain classes of beneficiaries from enrolling.  CMS encourages 
continuing discussion of its specialty tier policy and the need for rulemaking.30
Reference-Based Pricing:  CMS eliminates the practice of reference based 
pricing for 2010.  Under this practice, plan sponsors require beneficiaries to pay a 
cost-sharing amount in addition to the tiered-cost sharing for designated brand 
name drugs.  The practice generated confusion among beneficiaries during the 
fall 2008 annual enrollment period due to the lack of transparency of the actual 
price of their drugs. 
Utilization Management:  The Call Letter includes plan submission requirements 
to make it easier for CMS to review new 2010 or modified 2009 utilization 
management criteria.  It also includes additional directions, based on common 
errors in previous submissions that sponsors must follow in order to be compliant 
with CMS guidance.   
CMS will return formulary submissions with utilization management criteria that 
are inconsistent with widely used treatment guidelines or which have significant 
quality control issues.  Such submissions may be subject to a focused audit to 
determine whether the plan’s Pharmacy and Therapeutic Committee reviewed 
the criteria before submission.  Plans that continue the practice, as identified for 
plan year 2009, of attempting to use prior authorization criteria to limit access to 
only some of the FDA-approved labeled indications will have their criteria 
returned.  The criteria will be rejected if the plan sponsor does not submit 
reasonable justifications. Plans will not be allowed to require enrollees to try an 
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off-label indication first unless the off-label use is supported by guidelines that 
represent best practices. Plans are warned against criteria such as requiring an 
enrollee to try and fail more than two formulary alternatives to the prescribed 
medicine.
CMS warns sponsors that it will return formulary submissions without review if 
there are many errors or if the sponsor fails to follow CMS guidance, with the 
result that their formularies may not be filed in time.  CMS also reminds sponsors 
that it will continue to evaluate utilization management criteria against exceptions 
and appeal statistics and beneficiary complaints to determine whether they meet 
current medical practice and allow access to covered drugs. 
To promote additional transparency of utilization management criteria, CMS is 
also requiring plan sponsors to post submitted step therapy requirements on their 
web sites.  In 2009, CMS required the posting of prior authorization criteria. 
The Call Letter language concerning utilization management criteria addresses 
some but not all of the problems beneficiaries encounter.  CMS in the future 
could preclude sponsors from applying such criteria to all of the drugs in a 
particular category or class.  CMS also could clarify problems with the plan 
sponsors’ application of the exception and appeals process to utilization 
management criteria.  For example, some plans that impose multiple criteria on 
one drug will require a beneficiary who seeks an exception for one criterion, for 
example prior authorization, to then seek a second exception for the second 
criterion in order to get access to the drugs.  Additionally, CMS could clarify the 
relationship between prior authorization, on the one hand, and step therapy and 
quantity limits on the other. 
Medication Therapy Management (MTM): For the first time, the Call Letter 
provides detailed requirements for MTM programs.  The requirements address 
enrollment, targeting, intervention and outcomes-reporting and are based on 
what CMS identified as best practices in these areas.  CMS states that all Part D 
sponsors, with the exception of PFFS plans, must follow the requirements in 
establishing their program.  CMS reminds PFFS plans that they have an equal 
responsibility to provide a quality drug benefit and, using language common to 
previous Call Letters, encourages PFFS organizations to establish their own 
MTM programs.
Starting in 2010, plans must enroll beneficiaries in an MTM program with an opt-
out process.  The plans must target beneficiaries for enrollment at least quarterly, 
and the plans cannot require targets of the MTM program to have more than 
three chronic diseases.  The Call Letter includes a list of seven core chronic 
diseases to target.  Sponsors will be expected to have procedures to increase 
participation and to reach targeted enrollees through various approaches.  CMS 
reduces from $4,000 to $3,000 the minimum annual cost threshold that targeted 
individuals are likely to incur. 
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The Call Letter includes minimum services to be included as part of the MTM 
program.  It also includes requirements as to the services to be measured and 
reported to CMS.  CMS expects sponsors to analyze and evaluate their 
programs and make continuous improvements. 
The standards included in the Call Letter result from reviews conducted by CMS 
of current MTM programs.  The fact that CMS mandates requirements and 
standards is a departure from previous policies towards the design of the Part D 
benefit.
LOW-INCOME SUBSIDY (LIS) POLICY 
The 2010 Call Letter contains only a limited discussion of LIS policy issues.  For 
example, it does not describe new requirements for plans concerning the best 
available evidence (BAE) process for beneficiaries to establish that they are 
eligible for the low-income subsidy.   The provisions in this section provide no 
indication of potential policy shifts for LIS-eligible beneficiaries.  
Reassignment of LIS-eligible Individuals:  Re-assignment of LIS-eligible 
individuals when their PDP fails to qualify as an LIS plan for the following plan 
year remains a problem.  The Call Letter states that CMS expects to reassign 
LIS-eligible individuals again in the fall of 2009.  It also states that CMS will work 
with plans to reach out to their enrollees who are being reassigned to explain 
how to remain in the plan and their potential premium liability. 
CMS says it is continuing to study the problem of reassignment.  The agency 
encourages suggestions to improve the process that are consistent with its 
existing statute. 
Retroactive Auto-Enrollment of Full Benefit Dual Eligible Individuals:  The Call 
Letter describes the intention of CMS to implement in 2010 a demonstration 
contract to assign new full benefit dual eligible beneficiaries with retroactive 
coverage to a single contractor for the retroactive periods.  The demonstration 
does not address reimbursement issues for all LIS-eligible individuals who paid 
premiums and cost-sharing out-of-pocket while their Medicaid or LIS applications 
were pending. 
SECTION C – MARKETING/BENEFICIARY COMMUNICATIONS
Reports of unscrupulous marketing practices by some MA plans and PDPs, their 
brokers, and agents have generated publicity since the Part D program began in 
2006.  MIPPA included provisions addressing some of the problems. CMS has 
issued memoranda and other marketing guidance, as well as rules to implement 
the MIPPA changes.  The agency has taken corrective action measures against 
plans that violate marketing rules.  CMS has also used the Call Letter as a 
22
vehicle to provide updates and clarifications about permissible and non 
permissible marketing practices. 
The 2010 Call Letter, as in past Call Letters, addresses marketing problems.  It 
includes a list of some of the surveillance activities the agency has under taken 
and will continue in order to monitor marketing activities.  The Marketing section 
begins with the following:
“CMS will not accept any continued attempts by some in the industry to 
avoid complying with our marketing requirements and guidance.  CMS will 
take very strong action against any entity attempting to circumvent our 
rules.”
It concludes with the reminder: 
“…[R]epeated violations that demonstrate a pattern of misconduct will be 
considered more substantial violations than those that merited initial 
noncompliance notices and warning letters this past [Annual Enrollment Period.]” 
The Marketing section of the 2010 Call Letter contains strong language to 
encourage plan sponsors to comply with marketing requirements. 
Payment of Agents:   Before the 2008 Annual Enrollment Period, agents received 
substantially higher commissions and other remuneration for enrolling 
beneficiaries in MA plans than in PDPs. This disparity in compensation rates was 
considered one of the factors that induced agents to engage in marketing 
abuses.31 As a result, CMS, as required by MIPPA, published rules in September 
2008 and additional guidance throughout the fall enrollment period concerning 
agent compensation. 
The 2010 Call Letter provides two clarifications to plan sponsors about one of the 
provisions of the new rules concerning the amount that can be paid to agents 
and brokers.  One clarification allows plan sponsors to pay agents their base fee 
for 2009 before CMS issues reports identifying new enrollees to PDPs or MA 
plans, with adjustments made after the reports are released.  The other is a 
direction to cease immediately attempts to circumvent the new agent 
compensation limits by paying exorbitant referral fees to agents.  CMS 
emphasizes that the practice is out of compliance with its new regulations and 
guidance and cites its new regulatory provision. 
Marketing Materials: CMS reminds plan sponsors that all marketing materials 
must be reviewed and approved by CMS before they are used, including third 
party marketing materials developed by agents and others.  The Call Letter 
creates an exception for generic materials that do not discuss plan specific 
information.  CMS could do limited spot checking of such materials to ensure that 
plans and agents do not take advantage of this exception. 
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CMS announces in the Call letter that it will make minor changes to some Part D 
marketing materials for 2010 and will release the updated materials at a later 
date.  Some of the proposed changes are designed to provide beneficiaries with 
more information.  They include an indication in the evidence of coverage of the 
formulary cost-sharing tiers to which drugs that were approved as part of the 
exception process will be assigned, and a new model notice to be used when 
plans transfer prescriptions from network retail pharmacies to network mail-order 
pharmacies without enrollee consent.
Standardization of Plan Name Type:  For plan years that begin on January 1, 
2010, MIPPA requires all MA plans and PDPs to include the plan type as part of 
their name.  As required by MIPPA, CMS developed standard terminology to be 
used as part of the name, and included the list in the Call Letter.  There are 18 
different plan types listed.  The list does not account for the benefit package 
variations within each of these types of plans.  Not all beneficiaries are eligible to 
enroll in all plan types, and not all plan types will be available in every part of the 
country.  CMS could use the list as a starting point for discussions on the 
advisability of limiting the number of plans each sponsor may offer and 
developing standardized benefit packages.  
Other Marketing Activities:  As part of its continued vigilance over marketing 
activities, CMS could take additional steps to improve the information provided to 
beneficiaries.  These range from adopting the recommendations in the White 
Paper developed by the National Association of Insurance Commissioners 
(NAIC)32 to precluding marketing after the end of the statutory enrollment period.  
Many marketing violations may occur after that time period.  For example, agents 
may target PDP members who are unhappy with their drug coverage to 
encourage them to enroll in an MA plan, or may target beneficiaries who are 
eligible for a special enrollment period.
CONCLUSION
The 2010 Call Letter provides insights into how the new administration may 
interact with Medicare Advantage and Part D prescription drug plans. It 
emphasizes compliance with rules, regulations, and guidance. CMS 
acknowledges that some problem areas warrant additional consideration, and 
seeks input on how to make the program work more efficiently for beneficiaries, 
plan sponsors, and health care providers. CMS confirms its commitment to 
continue and strengthen its oversight of marketing activities and other areas such 
as enrollment and appeals, to help beneficiaries understand health plan options 
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